Clinical trials targeting TNF-α using etanercept or infliximab in heart failure (e.g., RENAISSANCE, RECOVER, RENEWAL and ATTACH) were prematurely terminated due to the lack of beneficial outcomes or, in some instances, worse outcomes for patients (Chung et al., 2003; Mann et al., 2004). The gene discussed is TNF; the disease is heart failure.